Premenstrual dysphoric disorder (PMDD) is a severe and disabling form of
premenstrual syndrome affecting 3–8% of women. The disorder consists of a "cluster of affective, behavioral and somatic symptoms" that recur monthly during the
luteal phase of the
menstrual cycle. PMDD was added to the list of depressive disorders in the Diagnostic and Statistical Manual of Mental Disorders V in 2013. The exact pathogenesis of the disorder is still unclear and is an active research topic. Treatment of PMDD relies largely on antidepressants that modulate serotonin levels in the brain via serotonin reuptake inhibitors as well as ovulation suppression using contraception.